PE20120899A1 - Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b - Google Patents
Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3bInfo
- Publication number
- PE20120899A1 PE20120899A1 PE2011001908A PE2011001908A PE20120899A1 PE 20120899 A1 PE20120899 A1 PE 20120899A1 PE 2011001908 A PE2011001908 A PE 2011001908A PE 2011001908 A PE2011001908 A PE 2011001908A PE 20120899 A1 PE20120899 A1 PE 20120899A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- nos
- complement protein
- compositions
- methods
- Prior art date
Links
- 102000000989 Complement System Proteins Human genes 0.000 title 1
- 108010069112 Complement System Proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17586009P | 2009-05-06 | 2009-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120899A1 true PE20120899A1 (es) | 2012-08-03 |
Family
ID=43063291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001908A PE20120899A1 (es) | 2009-05-06 | 2010-05-05 | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b |
Country Status (22)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| BRPI0712987A2 (pt) | 2006-06-21 | 2012-04-10 | Musc Found For Res Dev | tratamento de doenças direcionado ao fator h do complemento |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| NZ600393A (en) | 2009-11-05 | 2014-08-29 | Alexion Cambridge Corp | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| CA2803588A1 (en) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the c3d fragment of complement component 3 |
| EP2646821A4 (en) * | 2010-11-29 | 2015-09-23 | Novelmed Therapeutics Inc | NEOANTIC BODY FOR THE DIAGNOSIS OF TISSUE INJURY |
| WO2013152024A1 (en) * | 2012-04-03 | 2013-10-10 | Novelmed Therapeutics, Inc | Humanized and chimeric anti-factor c3 antibodies and uses thereof |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| PT2914291T (pt) | 2012-11-02 | 2022-05-05 | Bioverativ Usa Inc | Anticorpos anti-complemento c1s e suas utilizações |
| KR20150088853A (ko) | 2012-11-29 | 2015-08-03 | 바이엘 헬스케어 엘엘씨 | 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도 |
| JP6505079B2 (ja) | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| KR102448976B1 (ko) | 2013-08-07 | 2022-09-29 | 알렉시온 파마슈티칼스, 인코포레이티드 | 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질 |
| WO2015054298A1 (en) * | 2013-10-07 | 2015-04-16 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
| EP3086809A4 (en) | 2013-12-24 | 2017-11-29 | NovelMed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| JP6643244B2 (ja) | 2014-02-27 | 2020-02-12 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 補体因子Ｂｂ抗体 |
| US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| CN116554320A (zh) | 2016-10-12 | 2023-08-08 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| EP3526248A4 (en) | 2016-10-17 | 2020-07-08 | Musc Foundation for Research Development | COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE |
| AU2019248557A1 (en) | 2018-04-03 | 2020-09-24 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
| EP4257602A3 (en) * | 2018-06-11 | 2023-12-27 | Aarhus Universitet | Single domain antibodies for complement regulation |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CN117295766A (zh) * | 2021-03-19 | 2023-12-26 | 艾佩斯瑞生物制药公司 | 对唾液酸结合性ig样凝集素15具特异性的抗体及其用途 |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| AU2022420788A1 (en) | 2021-12-22 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| EP4590697A2 (en) * | 2022-09-20 | 2025-07-30 | Visterra, Inc. | Treatment of complement mediated diseases and disorders with c3b-antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2316446T3 (es) * | 2000-04-29 | 2009-04-16 | University Of Iowa Research Foundation | Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular. |
| US7838165B2 (en) * | 2004-07-02 | 2010-11-23 | Kabushiki Kaisha Toshiba | Carbon fiber synthesizing catalyst and method of making thereof |
| US20090004183A1 (en) * | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| MX2007006593A (es) * | 2004-12-02 | 2008-03-04 | Domantis Ltd | Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos. |
| KR20150139636A (ko) * | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| GB0613209D0 (en) * | 2006-07-03 | 2006-08-09 | Ucb Sa | Methods |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| MX2009013082A (es) * | 2007-06-07 | 2010-01-15 | Genentech Inc | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. |
| CL2008003241A1 (es) * | 2007-11-02 | 2009-07-31 | Novartis Ag | Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares |
-
2010
- 2010-05-04 US US12/773,246 patent/US20100291106A1/en not_active Abandoned
- 2010-05-05 MA MA34415A patent/MA33402B1/fr unknown
- 2010-05-05 WO PCT/EP2010/056129 patent/WO2010136311A2/en not_active Ceased
- 2010-05-05 CA CA2760757A patent/CA2760757A1/en not_active Abandoned
- 2010-05-05 KR KR1020117029046A patent/KR20120088551A/ko not_active Withdrawn
- 2010-05-05 AR ARP100101527A patent/AR076655A1/es not_active Application Discontinuation
- 2010-05-05 AU AU2010252156A patent/AU2010252156A1/en not_active Abandoned
- 2010-05-05 EA EA201101593A patent/EA201101593A1/ru unknown
- 2010-05-05 JP JP2012509035A patent/JP2012525829A/ja active Pending
- 2010-05-05 TW TW099114417A patent/TW201043638A/zh unknown
- 2010-05-05 EP EP10747599A patent/EP2427491A2/en not_active Withdrawn
- 2010-05-05 SG SG2011080330A patent/SG175432A1/en unknown
- 2010-05-05 CN CN201080026538XA patent/CN102459334A/zh active Pending
- 2010-05-05 MX MX2011011754A patent/MX2011011754A/es not_active Application Discontinuation
- 2010-05-05 PE PE2011001908A patent/PE20120899A1/es not_active Application Discontinuation
- 2010-05-06 UY UY0001032612A patent/UY32612A/es not_active Application Discontinuation
-
2011
- 2011-10-14 ZA ZA2011/07551A patent/ZA201107551B/en unknown
- 2011-10-19 TN TNP2011000528A patent/TN2011000528A1/en unknown
- 2011-10-31 IL IL216061A patent/IL216061A0/en unknown
- 2011-11-04 CO CO11150255A patent/CO6440515A2/es not_active Application Discontinuation
- 2011-11-04 CL CL2011002756A patent/CL2011002756A1/es unknown
- 2011-11-08 EC EC2011011445A patent/ECSP11011445A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11011445A (es) | 2012-01-31 |
| CL2011002756A1 (es) | 2012-03-23 |
| EA201101593A1 (ru) | 2012-06-29 |
| IL216061A0 (en) | 2012-01-31 |
| CO6440515A2 (es) | 2012-05-15 |
| EP2427491A2 (en) | 2012-03-14 |
| TW201043638A (en) | 2010-12-16 |
| CA2760757A1 (en) | 2010-12-02 |
| US20100291106A1 (en) | 2010-11-18 |
| SG175432A1 (en) | 2011-12-29 |
| UY32612A (es) | 2010-12-31 |
| AR076655A1 (es) | 2011-06-29 |
| MX2011011754A (es) | 2011-11-29 |
| MA33402B1 (fr) | 2012-07-03 |
| ZA201107551B (en) | 2012-07-25 |
| WO2010136311A2 (en) | 2010-12-02 |
| WO2010136311A3 (en) | 2011-05-26 |
| AU2010252156A1 (en) | 2011-11-10 |
| TN2011000528A1 (en) | 2013-05-24 |
| JP2012525829A (ja) | 2012-10-25 |
| CN102459334A (zh) | 2012-05-16 |
| KR20120088551A (ko) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| AR123876A2 (es) | Composición farmacéutica de anticuerpos anti-cgrp | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| PE20130393A1 (es) | Anticuerpos con union de antigenos dependiente de ph | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20140814A1 (es) | Anticuerpos contra la angiopoyetina 2 humana | |
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20120014A1 (es) | Anticuerpos humanos de alta afinidad contra pcsk9 | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |